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Mortality rate, life expectancy, survival, and the impact of comorbidities on them in people with Parkinson’s disease (PD) need
to be assessed in settings with different sociodemographic backgrounds. We investigated mortality features in Iranian PD patients
focusing on the role of cardiovascular multimorbidity on their survival. Data on mortality and comorbidity profile was gathered
in a cohort of 190 individuals with idiopathic PD referred to a Movement Disorders Clinic. Standardized mortality ratio (SMR)
compared to the Tehran general population was 3.44 and the life expectancy at birth was 67.4 (95% CI: 59.1–75.8) yr. Patients with
at least one cardiovascular comorbidity had a shorter survival time after PD onset (14.0 versus 29.2 yr, 𝑝 = 0.012). The hazard ratio
for death increased 2.8 times (95% CI: 1.5–5.2, 𝑝 = 0.002) with one additional cardiovascular comorbidity. Among all comorbid
conditions, stroke showed the strongest independent effect on mortality in PD patients [HR = 13.1 (95% CI: 2.4–71.7), 𝑝 = 0.003].
Conclusively, life expectancy was slightly lower in Iranian PDpatients compared to the general population, while the SMRwas high.
Cardiometabolic multimorbidity substantially decreased survival in people with PD. Our study highlights the need for assessment,
prevention, and treatment of cardiovascular morbidities in parkinsonian patients, given their effect on survival.
1. Introduction
Parkinson’s disease (PD) is not a life-threatening illness by
itself, but it may augment the risk of death through advanced
complications such as aspirations, deep vein thrombosis,
and pulmonary embolism during the end-stage phase in
immobile patients or by serious falling inmoderate-to-severe
cases [1]. Even though the rate of progression considerably
varies from one PD patient to another, they are expected
to experience often about the same life expectancy as for
the general population particularly among those who do not
develop dementia and receive timely management and care
[2]. Based on a recent meta-analysis, most studies reported
increased mortality in PD (compared to general population)
with a ratio ranging from 0.9 to 3.8 [3–6], while some others
showed lower ratios, too [7, 8].
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Several factors should be considered while studying mor-
tality features in PDpatients includingmethodological issues,
study design, choice of study population, and comorbid
conditions. End-stage PD patients are often frail elderly with
high potentiality of having other chronic diseases; however,
the role of comorbid disorders as a potential important driver
for higher mortality has been commonly ignored in people
with PD. It is still unclear how and to what extent does
cardiometabolic and cerebrovascular multimorbidity affect
life span and survival in PD patients. On the other hand,
differences in life expectancy and mortality rates of general
population from countries with diverse sociodemographic
characteristics necessitate the evaluation ofmortality features
in PD patients who are selected from different populations.
Therefore, we aimed at firstly investigating mortality features
in Iranian patients with PD and then focusing on the role
of cardiometabolic and cerebrovascular comorbidities on
survival in PD.
2. Methods and Materials
2.1. Setting and Participants. This study was performed
during January 2012 and September 2012 as a collaborative
project between Karolinska Institutet, Stockholm, Sweden,
and Iran University of Medical Sciences (IUMS), Tehran,
Iran. Target study population was defined as Iranian patients
with idiopathic Parkinson’s disease (IPD) and study samples
consisted of 190 IPD patients recruited from an outpatient
referral Movement Disorder Clinic in Tehran, Iran. IPD
was diagnosed by a neurologist specialized in movement
disorders using theUKBrain Bank criteria [9]. In this project,
all registered IPD patients during 2009-2010 were reassessed
using their medical records and filling a checklist through
telephone interviews.
2.2. Assessment. Patients’ age at PD diagnosis, current age,
or age at the time of death, sex, family history of parkin-
sonism, level of education, marital status, and treatment
protocol were recorded. Moreover, information on comorbid
conditions including heart failure, hypertension, diabetes,
stroke, respiratory diseases, depression, and dementia was
also gathered for each case. Patients’ recent health status as
dead or alive was determined through telephone interview.
A new variable was created counting the total number
of cardiovascular comorbidities consisting of heart failure,
hypertension, diabetes, and stroke, which vary between 0–4.
2.3. Statistical Analysis. Data were analyzed using SPSS
software version 17.0 (Chicago, IL, USA) and LifeTab Excel
softwares. In order to describe continuous and categorical
variables, mean [standard deviation (SD)] and frequency
(percentage) were used, respectively. Based on the number of
death events in each age category, age-specific mortality rates
were calculated and then standardized using “WHO World
Standard Population” as described elsewhere [10]. Following
the extraction of life table, life expectancy at birth (𝑒
0
)
and its 95% confidence interval (CI) were calculated using
the method recommended by “Office for National Statistics”
(ONS) [11]. Kaplan-Meier analysis was applied to compute
the mean survival time after the time of disease onset in
IPD patients.We used log-rank statistic to compare themean
survival time between study subgroups. Multivariate Cox
regression model was performed to indicate the factors that
could independently affect survival time after PD diagnosis
from a list of comorbid conditions and baseline character-
istics entered into the model as predictors. In all analytical
procedures, a two-sided 𝑝 value < 0.05 was considered as the
statistical significant level.
3. Results
3.1. Baseline Characteristics. Data from 190 patients consist-
ing of 131 (68.9%)males and 59 (31.1%) females were assessed.
The mean age at the onset of PD was 55.5 (SD = 12.1) yr and
the average duration of disease was 8.1 (SD = 5.0) yr ranging
between 1 and 30 years. Table 1 summarizes the baseline
and clinical characteristics of the entire study population.
Majority of patients (96.3%) were under treatment with
levodopa, while deep brain stimulation (DBS) was performed
only in 8 (4.2%) cases. Depression (46.0%) and hypertension
(20.1%) were the most common comorbidities.
3.2. Mortality Rate and Life Expectancy. Twelve patients were
dead at the time of investigation and the mean age at the time
of death was 71.4 (SD = 10.6) yr ranging from 51 to 87 years.
As shown in Figure 1, the age-specific mortality rate raised
gradually by age with a large increase in the “70–74 yr” age
category. Following adjustment with “WHO World Standard
Population,” the age-standardized mortality rate was calcu-
lated as 2777.9 per 100,000 (95% CI: 1206.2–4349.7/100,000)
in the whole study population, 2481.3/100,000 for the males
and 4885.1/100,000 for the females. Considering recent data
on age-specific mortality rate in Tehran general population
[12], the standardized mortality ratio was calculated as 3.44
in recruited PD population. Using the ONS method on life
table data, the life expectancy at birth was computed as 67.4
(95% CI: 59.1–75.8) yr in the entire PD population, 70.2 (95%
CI: 59.2–81.2) yr in male PD patients, and 64.9 (95%CI: 50.7–
79.2) yr in female PD patients.
3.3. Survival Analysis. Kaplan-Meiermethod showed that the
mean survival time after PD diagnosis was 25.7 (95% CI:
22.4–29.0) yr. Though the mean follow-up time was shorter,
there were few patients with as long as 30 years of follow-up
who had not met the outcome yet. These patients have been
taken into account for the predictionmodeling of the survival
analysis. Table 2 shows the findings from multivariate Cox
regression models. Among all comorbid conditions, stroke
had the strongest independent effect on mortality in PD
patients [HR = 13.1 (95% CI: 2.4–71.7), 𝑝 = 0.003]. His-
tory of having any cardiovascular comorbidity significantly
increased the hazard for death [HR = 4.6 (95% CI: 1.1–
18.7), 𝑝 = 0.033]. As illustrated in Figure 2, PD patients
with at least one cardiovascular comorbidity had a shorter
survival time after the time of PD onset [14.0 (95% CI: 13.2–
14.9) yr versus 29.2 (95% CI: 28.2–30.2) yr]. Result from the
log-rank test demonstrated that this difference is statistically
significant (Chi2 = 6.4,𝑝 = 0.012). Cox regressionmodel also
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Table 1: Baseline and clinical characteristics of the recruited Parkinson’s disease patients.
Characteristics Total (𝑛 = 190)
Current age (or death age) (yr) mean (SD) 63.6 (11.0)
Age at the time of diagnosis (yr) mean (SD) 55.5 (12.1)
Sex𝑁 (%)
Female 59 (31.1)
Male 131 (68.9)
Family history of parkinsonism𝑁 (%) 31 (16.4)
Level of education𝑁 (%)
Illiterate 17 (9.1)
Primary and/or secondary 63 (33.7)
High school/diploma 51 (27.3)
College and/or university 56 (29.9)
Marital status𝑁 (%)
Single 9 (5.6)
Married 127 (78.9)
Widow or divorced 25 (15.5)
Treatment history𝑁 (%)
Levodopa 181 (96.3)
Amantadine 70 (37.2)
Selegiline 16 (8.5)
Bipyridine 6 (3.2)
Other dopaminergic drugs (i.e., ropinirole and pramipexole) 58 (30.9)
Deep brain stimulation (DBS) 8 (4.2)
Comorbidities𝑁 (%)
Heart failure 34 (18.0)
Hypertension 38 (20.1)
Diabetes 24 (12.7)
Stroke 10 (5.3)
Respiratory diseases 20 (10.6)
Depression 87 (46.0)
Dementia 36 (19.0)
Table 2: Cox regression models to find independent factors predicting mortality in recruited Parkinson’s disease patients.
Variables
Model 1 Model 2 Model 3
Hazard
ratio (HR)
95% CI for HR
𝑝 value Hazardratio (HR)
95% CI for HR
𝑝 value Hazardratio (HR)
95% CI for HR
𝑝 value
Lower Upper Lower Upper Lower Upper
Male gender 0.79 0.17 3.66 0.766 0.60 0.16 2.22 0.442 0.56 0.15 2.08 0.385
Dementia 0.62 0.06 6.19 0.685 0.45 0.05 3.89 0.470 0.51 0.06 4.58 0.549
Depression 0.51 0.12 2.09 0.346 0.63 0.17 2.32 0.491 0.49 0.12 1.93 0.306
Respiratory
diseases 0.22 0.02 3.32 0.275 0.71 0.08 5.99 0.754 0.46 0.05 4.27 0.498
Hypertension 2.74 0.60 12.64 0.195 — — — — — — — —
Diabetes 0.87 0.13 5.61 0.882 — — — — — — — —
Heart failure 2.61 0.57 12.10 0.219 — — — — — — — —
Stroke 13.13 2.40 71.74 0.003 — — — — — — — —
Having car-
diovascular
comorbidity
— — — — 4.60 1.13 18.72 0.033 — — — —
Number of
cardiovascu-
lar
comorbidities
— — — — — — — — 2.75 1.45 5.21 0.002
4 Parkinson’s Disease
0
2500
5000
7500
10000
12500
15000
17500
20000
22500
25000
2
5
–2
9
3
5
–3
9
4
0
–4
4
4
5
–4
9
5
0
–5
4
5
5
–5
9
6
0
–6
4
6
5
–6
9
7
0
–7
4
7
5
–7
9
8
0
+
Figure 1: Age-specific mortality rates (per 100,000) in recruited
Iranian Parkinson’s disease patients.
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Figure 2: Survival curve in Parkinson’s disease patients with (red
line) and without (blue line) any cardiovascular comorbidity (𝑝
value for log-rank test = 0.012).
demonstrated that with one extra number of cardiovascular
comorbidities the hazard for death significantly increased by
2.8 times (95% CI: 1.5–5.2, 𝑝 = 0.002). As illustrated in
Figure 3, the longest survival time after PDdiagnosiswas seen
among those without any cardiovascular comorbidity [29.2
(95% CI: 28.2–30.2) yr], whereas the shortest survival time
was calculated for those with three cardiovascular comorbid
diseases [7.7 (95%CI: 6.9–8.4) yr].These differences were also
shown to be statistically significant by log-rank test (Chi2 =
18.2, 𝑝 < 0.001).
4. Discussion
Our study showed slightly lower (≈1 yr) life expectancy at
birth in Iranian PD patients compared to the reports for
general Iranian population at almost the same time point
(2011-2012), which has been estimated to be 68.6 and 71.6 yr in
males and females [13], respectively.However, our sample size
for a more valid calculation of life expectancy is rather small
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Figure 3: Mean survival time in recruited patients after Parkinson’s
disease diagnosis regarding the presence and/or number of cardio-
vascular comorbidities (𝑝 value for log-rank test < 0.001).
and its wide confidence interval includes the estimations for
general population. Considering mortality rate in general
population of Tehran, where the referral outpatient clinic is
located, the SMR for recruited PD patients in our study was
estimated as 3.44. Previous investigations have demonstrated
a wide range of SMR for different PD populations ranging
from 1.52 in Norway [14] to 3.38 in Taiwan [15] showing that
our estimation for this group of Iranian PD patients is a high
SMR.
We investigated the impact of cardiovascular comorbidi-
ties on survival in patients with PD, which demonstrated
that the presence of cardiovascular comorbidity considerably
reduces survival and increases hazard ratio for death by
approximately five times. In a so-called “dose-response”
effect, an addition of one cardiometabolic and/or cerebrovas-
cular comorbidity accompaniedwith extra three times higher
hazard risk of death in PD patients. Among all comorbid
conditions, stroke showed the strongest independent adverse
effect on mortality in people with PD. Furthermore, in this
retrospective cohort of PD patients, we found that older age
and female gender were associated with higher mortality
risk. Though the independent effect of female sex on shorter
survival time in our study was not statistically significant in
further multivariate analysis, there are some few recent stud-
ies investigating gender differences in PD demonstrating a
more severe course of PD in female patients [16]. More severe
dyskinesia [17], more postural instability [18], more frequent
freezing [19], more levodopa resistance [17], higher preva-
lence of depression [20, 21], and worse quality of life [22]
could all contribute to shorter survival in female PD patients.
There are several studies that have investigated predictors
of survival in PD, which resulted in inconsistent findings
regarding the list of variables that they have measured. Yet,
few of them have focused on the role of cardiovascular
multimorbidity on mortality and survival in parkinsonian
patients. One study has reported that terminal PD patients
were hospitalized more frequently due to cardiovascular dis-
eases and infection and rarely for PD-related complications
[23]. Recent epidemiologic investigations have suggested that
PD itself is associated with certain vascular risk factors such
as diabetes [24, 25] and hypertension [26]. In our study,
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PD patients with at least one cardiovascular comorbidity
had substantially shorter survival time after the time of PD
onset (14 versus 29 yr). Similar to our findings, Ben-Shlomo
and Marmot have reported that both ischemic heart disease
(HR = 2.3, 95% CI: 1.5–3.4) and stroke (HR = 3.6, 95% CI:
2.2–6.1) significantly increased hazard ratio for mortality in a
cohort of 220PDpatients [27].On the contrary, another study
showed no difference in the risk of death due to ischemic
heart disease in PD patients after adjustment for age and
gender (relative risk = 1.1, 95% CI: 0.6–2.0) [7].
In line with our findings from PD patients, researchers
have quite recently demonstrated that any combination of
cardiometabolic comorbidities such as diabetes, heart failure,
and stroke associated with multiplicative mortality risk and
reduced life expectancy in general population [28]. A cohort
of 6504 individuals in Iran revealed that cardiovascular
disease mortality constituted 31.8% of all-cause mortality in
both men and women [29]. Some studies have enquired
cardiovascular risk in individuals with and without PD. In a
prospective population-based survey, cardiovascular diseases
were the most frequent cause of death in persons with PD,
and, in this respect, PD cases were similar to general pop-
ulation [30]. In another longitudinal study, cardiovascular
diseases were found to be the first cause of death, which
were attributed to the probable involvement of myocardium
through autonomic dysfunction in PD [31, 32].
We acknowledge the limitations of our study of which
the most important one refers to the limited list of vari-
ables that we have assessed. Several different combinations
of risk factors for mortality in PD have been evaluated;
however, we have mainly focused on the general features of
mortality in Iranian PD patients (i.e., life expectancy and
mortality rate) and the role of cardiovascular multimorbidity
on their survival. Validity of information could have been
also improved using more sophisticated methods such as
full neuropsychiatric assessment for cognitive status. This
might explain why, in contrast to previous studies that
have introduced dementia as an important risk factor for
shorter survival in PD [23, 33], our investigation failed to
show such association, which is mainly due to lack of valid
data on cognitive decline. Recruitment of patients from a
specialist clinic where extreme frail elderly and those with
lower socioeconomic status were less likely to be referred
might have restricted generalizability of our findings. The
proportion of participants who had not had the outcome
during the follow-up (censored data in survival analysis) is
high meaning that a longer follow-up duration is needed for
more robust estimation of mortality features in PD patients.
More in-depth information about the exact cause of death in
PD patients obtained from national death register could be
also helpful.
In conclusion, we showed that life expectancy might be
slightly lower in Iranian PD population and their SMR is
up to 3.44 compared to general population. Cardiometabolic
multimorbidity played an important role in PD patients’
survival such that each extra cardiovascular comorbidity
substantially increased risk of mortality. Our study highlights
the need for prevention and treatment of cardiovascular
disorders in parkinsonian patients, given their effect on
survival. Regarding the important role of cardiometabolic
morbidities, PD patients should confer protection against
the risk factors and consequences of common cardiovascular
diseases. Although neurologist care associates with improved
clinical outcomes and greater survival, less than half of PD
patients are referred to them [34] and it could be a possible
contributor to poor management of PD symptoms and
less precise screening of other common illnesses. Moreover,
physicians and patients may impute nonspecific symptoms
such as fatigue, weakness, or exercise intolerance to PD,
while they in fact represent other illnesses, like cardiovascular
diseases.
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